Genetic muscle disorder mimicking atrial arrhythmias with conduction defects requiring pacemaker implantation

Katarzyna Kalin¹, Artur Oręziak¹, Maria Franaszczyk², Zofia T. Bilinska³, Rafał Płoski², Maria Bilinska¹

1 Department of Arrhythmia, The Cardinal Stefan Wyszyński Institute of Cardiology, Warsaw, Poland
2 Department of Medical Biology, The Cardinal Stefan Wyszyński Institute of Cardiology, Warsaw, Poland
3 Unit for Screening Studies in Inherited Cardiovascular Diseases, The Cardinal Stefan Wyszyński Institute of Cardiology, Warsaw, Poland

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, which is associated with cardiovascular comorbidities, and its prevalence increases with age.¹ We present the case of a young 28-year-old man who was admitted due to newly diagnosed AF following pre-employment medical examination. He had no history of drug intake. He only complained of occasional dizziness and fatigue during vigorous activities. Upon further questioning, a history of weight loss despite increased food consumption in the last 6 months was elicited. Clinical examination revealed elevated blood pressure of 140/90 mm Hg, bilateral elbow and ankle contractures with asymmetric muscle wasting, especially of the right arm and left lower limb (figure 1A and 1B). In hindsight, the patient recalled this abnormality since his late teens, but no further investigations were done at that time. Family history was relevant with cases of a sudden unexplained death of male family members on his mother’s side before the age of 40 years. At the initial referral visit, the electrocardiogram demonstrated a regular junctional escape rhythm of 35 bpm and low amplitude baseline deflections suggestive of atrial flutter (Figure 1C). Holter 12-lead electrocardiogram monitoring confirmed episodes of AF, atrial flutter, atrial tachycardia with a slow ventricular response and significant pauses of up to 3.86 s. Doppler echocardiography revealed a normal left ventricular ejection fraction of 63%, marked biatrial enlargement, and complete absence of A waves that indicated loss of right and left atrial mechanical activity. Late gadolinium-enhanced cardiac magnetic resonance showed no signs of myocardial fibrosis or inflammation. Serum creatine kinase concentration was elevated at 724 U/l (reference range, 39–308 U/l) and high-sensitivity troponin T concentration was high at 90.32 ng/l (reference range <14 ng/l).

The constellation of the family and personal history as well as findings of physical examination and imaging findings suggested a diagnosis of Emery–Dreifuss muscular dystrophy (EDMD). Following genetic counseling,
Genetic tests performed in the mother, the mother’s sister, and a male cousin showed a hemizygous mutation suggesting the diagnosis of EDMD in the cousin and revealed that both women were heterozygous carriers (FIGURE 1D). On family assessment, the patient’s male cousin, aged 20, revealed joint contractures, mild limb muscle atrophy, and bradyarrhythmias, and both female relatives were asymptomatic.

Emery–Dreifuss muscular dystrophy is a condition characterized by the clinical triad of early-onset contractures, progressive weakness and wasting in humeroperoneal muscles, and cardiac disease with conduction defects, arrhythmia and cardiomyopathy. The disease has X-linked recessive inheritance pattern and thus typically affects men (cardiac disease may manifest in some female carrier as well).

The patient underwent testing of the EDMD gene, which encodes the muscle-specific emerin protein. Sanger sequencing revealed the hemizygous p.Ser52AlafsTer13/c.153delC mutation (FIGURE 1D), resulting in a premature truncation of the protein. As atrial electrical silence is frequently observed in EDMD, ablation could not be a therapeutic option for our patient. The patient was referred for pacemaker implantation. Once the right ventricular lead had been placed, electrical cardioversion of AF restored slow sinus rhythm temporarily and the patient had a permanent dual-chamber pacemaker implanted. Anticoagulation therapy was administered to prevent thromboembolic events, based on the assessment of stroke risk in patients with EDMD, the presence of hypertension, and the patient’s choice.
Due to the specific clinical manifestation (including muscle atrophy), EDMD could be categorized into group 2 (arrhythmias in specific clinical settings) and subgroup O (other) according to the classification of rare cardiovascular diseases and disorders (RCDD classification, VI-2O).5

Our case demonstrates that atrial arrhythmias may be the first clinical manifestation of EDMD. Appropriate clinical assessment together with taking into account a family history, serum levels of muscle-specific biomarkers and genetic testing may help to establish the primary cause of the disease.

ACKNOWLEDGMENTS This study was funded by the internal grant of the Cardinal Stefan Wyszyński Institute of Cardiology no. 2.54/11/15. ZTB was supported by a grant from ERA-CVD framework: DETECTIN-HF.

CONFLICT OF INTEREST None declared.

OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl.


REFERENCES


